echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > 【Classic literature reading】The effect of lidocaine infusion in thoracoscopic radical total pneumonectomy on chronic pain in patients after surgery

    【Classic literature reading】The effect of lidocaine infusion in thoracoscopic radical total pneumonectomy on chronic pain in patients after surgery

    • Last Update: 2022-10-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Effect of lidocaine perioperative infusion on chronic postsurgical pain in patients undergoing thoracoscopic radical pneumonectomy

    Effect of lidocaine infusion in thoracoscopic radical total pneumonectomy on chronic pain in patients after surgery

    by Dani & Miao & Cat


    Background: Thoracoscopic radical total pneumonectomy is associated
    with a high incidence of chronic pain after surgery.
    However, the benefits of intravenous lidocaine infusion during thoracoscopic surgery remain controversial
    .

    Methods: Sixty-four patients with lung cancer were randomly divided into normal saline group (control group) and lidocaine group
    .
    Lidocaine was given 1.
    5 mg/kg during anesthesia induction in the lidocaine group, and 2 mg·kg−1·h−1 lidocaine was continued intravenously until the end of
    surgery.
    Postoperative patient analgesic pump (formula: 2 μg/kg sufentanil + 10 mg/kg lidocaine for 100ml) continued intravenous infusion
    .
    The control group was given the same amount of normal saline
    for the calculation of lidocaine in anesthesia induction, maintenance, and postoperative self-control analgesia.
    Key results: incidence of
    chronic pain within 3 months postoperatively.
    Secondary outcomes: incidence of chronic pain at 6 months postoperatively, acute pain at 24 and 48 hours postoperatively, total amount of sufentanil, number of
    PCA triggers in 48 hours postoperatively.

    Results: The incidence of chronic pain in the lidocaine group was significantly reduced within 3 months after surgery (46.
    4% vs 20.
    7%, p<0.
    05).

    However, there was no significant difference
    between the two groups at within 6.
    The total amount of sufentanil in the perioperative period was significantly lower in the lidocaine group (149.
    64±18.
    20 μg vs139.
    47±16.
    75 μg) (p<0.
    05) but the number of triggers was more frequent (8.
    21±4.
    37 vs.
    5.
    83±4.
    12, p<0.
    05) There was no difference between
    the 24h and 48hNRS scores in the two groups.
    (1.
    68±0.
    72 vs.
    1.
    90±0.
    86) (1.
    21±0.
    42 vs.
    1.
    20±0.
    41)




    Figure&Table


    flow chart

    Baseline characteristics

    Occurrence and characteristics of chronic pain within 3 months after surgery

    Occurrence and characteristics of chronic pain within 6 months after surgery

    Intraoperative drug dosage comparison

    Original link

    https://doi.
    org/10.
    1186/s12871-022-01795-2


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.